Page-14
18. Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61(6):1385-1396.
19. Lario M, Muñoz L, Ubeda M, et al. Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis. J Hepatol. 2013;59(4):723-730.
20. Goel A, Verma A, Tiwari P, et al. Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield®) in Patients with Liver Cirrhosis. Vaccines (Basel). 2022;10(11):1837.
21. Mohammed AH, Blebil A, Dujaili J, Rasool-Hassan BA. 2020. The risk and impact of COVID-19 pandemic on immunosuppressed patients: Cancer, HIV, and solid organ transplant recipients. AIDS Rev . 22:151–157.
22. Lee ARYB, Wong SY, Chai LYA, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632.
23. Costiniuk CT, Singer J, Lee T, et al. COVID-19 vaccine immunogenicity in people with HIV. AIDS. 2023;37(1):F1-F10.
24. Reeg DB, Hofmann M, Neumann-Haefelin C, Thimme R, Luxenburger H. SARS-CoV-2-Specific T Cell Responses in Immunocompromised Individuals with Cancer, HIV or Solid Organ Transplants. Pathogens. 2023;12(2):244.
25. Good practice statement on the use of second booster doses for COVID-19 vaccines 18 August 2022 Background [Internet]. Available from: https://www.who.int/groups/strategic-advisory.